Racura Oncology Ltd · ASX:RAC
Racura Oncology — TechKnow Invest Conference 2026
16 slides from Racura Oncology's conference presentation, Jul 29, 2026
Slide 1: Racura Oncology to Present at TechKnow Invest Conference
ASX Announcement Racura Oncology to Present at TechKnow Invest Conference 29 July 2026 Racura Oncology Limited (“Racura”) is pleased to advise that CEO and Managing Director, Dr Daniel Tillett will be presenting at the TechKnow Invest Conference in Sydney on 29 July 2026 at 12.30pm. The TechKnow Inv
Slide 2: About Racura Oncology
About Racura Oncology Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer. Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that primarily acts by stabilising G4-DNA and RNA structures, drivi
Slide 3: Racura Oncology TechKnow Invest Roadshow
July 2026 Racura Oncology TechKnow Invest Roadshow Dr Daniel Tillett, CEO & MD
Slide 4: Important notice and disclaimer
Important notice and disclaimer The material in this presentation has been prepared by Racura Oncology Limited (ACN 149 318 749) (Company). THIS IS NOT A PROSPECTUS This presentation is not a prospectus, product disclosure statement or disclosure document for the purposes of the Corporations Act 200
Slide 5: Corporate snapshot
Corporate snapshot Racura Oncology is an ASX-listed, late-stage clinical biopharmaceutical company Racura 12-month trading history1 Key metrics ($A) ASX code RAC Share price $2.091 Market capitalisation $409.8m1 Cash at bank $34.3m2 Debt Nil Enterprise value $375.5m1 Shares on issue 196,068,9401 Opt
Slide 6: Why invest in Racura Oncology?
Why invest in Racura Oncology? Investment opportunity for Racura has fundamentally changed in recent times Clinically validated drug Improved drug - RC220 20yr composition of Bisantrene used in >50 Reformulated for better matter patent filed clinical trials. Established administration. 20 years of C
Slide 7: MYC: Oncology’s largest untapped opportunity
MYC: Oncology’s largest untapped opportunity Treating MYC dysregulation is a huge opportunity across numerous cancer types Major cancers with elevated MYC activity1 of all cancers have elevated MYC 70% activity MYC is a potent accelerator of cancer growth ü Discovered in 1982 ü Controls genes involv
Slide 8: (E,E)-bisantrene
(E,E)-bisantrene Binds and stabilises G-quadruplex DNA, silencing the c-MYC oncogene1 G-quadruplexes or G4 Key regulatory structures in DNA (& RNA) recognised by transcription and translation factors to regulate cell growth and division Double stranded DNA G-quadruplex (G4) DNA (double helix) 1. Rac
Slide 9: Scientific support for c-MYC gene silencing activity
Scientific support for c-MYC gene silencing activity (E,E)-bisantrene stabilises MYC G-quadruplex (G4) and turns off expression of c-MYC gene 4000 2000 M o l a r E l l ip t i c i ty ( ? ) 0 -2000 200 250 300 350 Wavelength (nm) G4 Melting Molecular Dynamics Surface Plasmon 1H-NMR Gene Expression Res
Slide 10: MYC inhibitors in the clinic
MYC inhibitors in the clinic RC220 competitors are all at early stage and have limited clinical activity Drug Developer Mechanism of action Clinical activity MYC Direct (protein/gene) Phase 3 AML, Phase 1 NSCLC, Phase 1 solid tumours; RC220 Racura Oncology G-quadruplex stabiliser 40% CR/PR in AML OM
Slide 11: Clinical Programs
Clinical Programs
Slide 12: Clinical pipeline
Clinical pipeline Three clinical programs in AML, lung cancer and solid tumours Total addressable Cancer indication Phase 1 Phase 2 Phase 3 Comment patients1 40% response rate in AML two Phase 2 trials3 Acute myeloid leukaemia2 US/EU: 50,000 Phase 3 Bisantrene approved in 1988 in France EGFRm lung c
Slide 13: Shared mechanism, multiple pathways to market
Shared mechanism, multiple pathways to market RC220’s shared MYC mechanism supports multiple oncology programs RC220 Program 1: Acute myeloid Phase 3 Program 2: EGFRm lung Phase 1 Program 3: Cardioprotection Phase 1 leukaemia (EMILI) cancer (HARNESS) & anticancer (CPACS) Monotherapy In combination w
Slide 14: Extreme value from clinical success with difficult targets
Extreme value from clinical success with difficult targets RAS provides a compelling precedent for MYC – value of success with major “undruggable” targets Stage at peak (all pre-revenue) Company Target Peak market value Outcome/ Status 1/1b 2 3 Approved 2023 - Acquired for KRAS G12C US$12B $US4.8bn
Slide 15: Multiple clinical and strategic catalysts through 2027
Multiple clinical and strategic catalysts through 2027 Upcoming milestones across AML, NSCLC, cardioprotection and mechanism validation ü MYC mechanism of action presented at AACR conference AML 1H26 ü CPACS dose escalation update released (Phase 3 ü First patient dosed in HARNESS-1 lung cancer tria
Slide 16: Contact
Contact DANIEL TILLET T JANE LOWE CEO & MD Investor & Media Relations +61 2 8051 3043 +61 411 117 774 daniel.tillett@racuraoncology.com jane.lowe@irdepartment.com.au ©2026 Racura Oncology Ltd. All rights reserved. The information contained in this presentation is current as at the date of publicatio